Market research
PRVL Prevail Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 788M
- P/E ratio
- Not available
- Analyst target
- 23.63
- Dividend yield
- 0.0%
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74140Y1010
- Market cap
- 788M
- P/E ratio
- Not available
- Analyst target
- 23.63
- Dividend yield
- 0.0%
- Beta
- Not available
About
About Prevail Therapeutics Inc
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PRVL discussion.
5 years, 4 months ago
Prevail Therapeutics Inc is currently in a long term uptrend where the price is trading 48.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Prevail Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 8.4% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.6% to $-17M since the same quarter in the previous year.
Based on the above factors, Prevail Therapeutics Inc gets an overall score of 4/5.